Beamr video compression achieves up to 50% improvement for AVs
Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (NASDAQ:WGS), recently sold a significant portion of the company's Class A common stock. According to a recent filing, Feeley sold shares worth approximately $1.43 million on April 9, 2025. The sales occurred at a price range between $83.07 and $97.26 per share, amid the company's impressive 741% surge over the past year. Based on InvestingPro analysis, the stock appears overvalued at its current market cap of $2.58 billion, trading at a high Price/Book ratio of 11.1x.
In addition to the sales, Feeley also acquired 1,246 shares through the exercise of stock options at a price of $32.67 per share, valued at $40,706. This transaction increased his direct ownership to 17,242 shares prior to the sales. The company maintains strong financial health with a current ratio of 3.6x and operates with moderate leverage, as indicated by its 0.47 debt-to-equity ratio.
The sales were conducted under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for selling shares, thereby helping to avoid any potential accusations of insider trading. After these transactions, Feeley holds 1,726 shares of GeneDx Holdings Corp. For deeper insights into insider trading patterns and 10+ additional key metrics, check out the comprehensive research report available on InvestingPro.
In other recent news, GeneDx Holdings Corp reported impressive financial results for the fourth quarter of 2024, significantly surpassing earnings and revenue expectations. The company achieved an earnings per share of $0.08, contrasting sharply with the anticipated loss of $0.48. Revenue reached $95.3 million, exceeding the forecasted $61.7 million. This marks the second consecutive quarter of profitability for GeneDx, with $16.8 million in adjusted net income. The company also reported a 101% year-over-year increase in exome and genome testing revenues. GeneDx recently launched an Ultra Rapid Whole Genome Sequencing product, further expanding its offerings. Additionally, the company has expanded its sales team and integrated new operational strategies to support its growth. Looking ahead, GeneDx has set its 2025 revenue guidance between $350 million and $360 million, with an expected growth of at least 30% in exome and genome volume.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.